Utidelone
- Generic Name
- Utidelone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic engineering. It is under investigation in clinical trials for various cancers.
- Indication
联合卡培他滨，用于既往接受过至少一种化疗方案的复发或转移性乳腺癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05052437
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath